

# Protocol for the Examination of Specimens from Patients with Carcinomas of the Salivary Glands

**Protocol applies to all invasive carcinomas of the parotid, submandibular, and sublingual glands. Melanomas, lymphomas, and sarcomas are not included. Minor salivary gland carcinomas are detailed in upper aerodigestive tract site specific protocols.**

---

**Based on AJCC/UICC TNM, 7th edition**  
Protocol web posting date: October 2009

## **Procedure**

- Biopsy
- Resection

## **Authors**

Bruce M. Wenig, MD, FCAP\*†

Department of Pathology and Laboratory Medicine. Beth Israel Medical Center, St. Luke's and Roosevelt Hospitals, New York, NY

Leon Barnes, MD

Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA

Diane L. Carlson, MD, FCAP\*

Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY

John Chan, MD, FCAP

Department of Pathology, Queen Elizabeth Hospital, Hong Kong

Gary Ellis, DDS

ARUP Laboratories, Salt Lake City, UT

Louis B. Harrison, MD

Department of Radiation Oncology, Beth Israel Medical Center, St. Luke's and Roosevelt Hospitals, New York, NY

Jennifer Leigh Hunt, MD, FCAP

Department of Pathology, Massachusetts General Hospital, Boston, MA

Mary S. Richardson, MD, DDS

Department of Pathology, Medical University of South Carolina, Charleston, SC

Jatin Shah, MD, FACS

Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY

Lester D. R. Thompson, MD, FCAP

Department of Pathology, Southern California Permanente Medical Group, Woodland Hills, CA

Richard Zarbo, MD, DMD, FCAP

Department of Pathology, Henry Ford Health Systems, Detroit, MI

For the Members of the Cancer Committee, College of American Pathologists

\*denotes primary author. † denotes senior author. All other contributing authors are listed alphabetically.

**Previous contributors:** Ben Z. Pilch, MD; Elizabeth Gillies, MD; John R. Houck Jr, MD; Kyung-Whan Min, MD; David Novis, MD; Jatin Shah, MD; Richard J. Zarbo, MD, DMD; Bruce M Wenig, MD

© 2009 College of American Pathologists (CAP). All rights reserved.

The College does not permit reproduction of any substantial portion of these protocols without its written authorization. The College hereby authorizes use of these protocols by physicians and other health care providers in reporting on surgical specimens, in teaching, and in carrying out medical research for nonprofit purposes. This authorization does not extend to reproduction or other use of any substantial portion of these protocols for commercial purposes without the written consent of the College.

The CAP also authorizes physicians and other health care practitioners to make modified versions of the Protocols solely for their individual use in reporting on surgical specimens for individual patients, teaching, and carrying out medical research for non-profit purposes.

The CAP further authorizes the following uses by physicians and other health care practitioners, in reporting on surgical specimens for individual patients, in teaching, and in carrying out medical research for non-profit purposes: (1) **Dictation** from the original or modified protocols for the purposes of creating a text-based patient record on paper, or in a word processing document; (2) **Copying** from the original or modified protocols into a text-based patient record on paper, or in a word processing document; (3) The use of a **computerized system** for items (1) and (2), provided that the Protocol data is stored intact as a single text-based document, and is not stored as multiple discrete data fields.

Other than uses (1), (2), and (3) above, the CAP does not authorize any use of the Protocols in electronic medical records systems, pathology informatics systems, cancer registry computer systems, computerized databases, mappings between coding works, or any computerized system without a written license from CAP. Applications for such a license should be addressed to the SNOMED Terminology Solutions division of the CAP.

Any public dissemination of the original or modified Protocols is prohibited without a written license from the CAP.

The College of American Pathologists offers these protocols to assist pathologists in providing clinically useful and relevant information when reporting results of surgical specimen examinations of surgical specimens. The College regards the reporting elements in the "Surgical Pathology Cancer Case Summary (Checklist)" portion of the protocols as essential elements of the pathology report. However, the manner in which these elements are reported is at the discretion of each specific pathologist, taking into account clinician preferences, institutional policies, and individual practice.

The College developed these protocols as an educational tool to assist pathologists in the useful reporting of relevant information. It did not issue the protocols for use in litigation, reimbursement, or other contexts. Nevertheless, the College recognizes that the protocols might be used by hospitals, attorneys, payers, and others. Indeed, effective January 1, 2004, the Commission on Cancer of the American College of Surgeons mandated the use of the checklist elements of the protocols as part of its Cancer Program Standards for Approved Cancer Programs. Therefore, it becomes even more important for pathologists to familiarize themselves with these documents. At the same time, the College cautions that use of the protocols other than for their intended educational purpose may involve additional considerations that are beyond the scope of this document.

The inclusion of a product name or service in a CAP publication should not be construed as an endorsement of such product or service, nor is failure to include the name of a product or service to be construed as disapproval.

**Surgical Pathology Cancer Case Summary (Checklist)**

---

Protocol web posting date: October 2009

**MAJOR SALIVARY GLANDS: Incisional biopsy, Excisional Biopsy, Resection****Select a single response unless otherwise indicated.****Specimen (select all that apply) (Note A)**

- ☐ Parotid gland
  - ☐ Superficial lobe only
  - ☐ Deep lobe only
  - ☐ Total parotid gland
- ☐ Submandibular gland
- ☐ Sublingual gland

**Received:**

- ☐ Fresh
- ☐ In formalin
- ☐ Other (specify): \_\_\_\_\_

**Procedure (select all that apply):**

- ☐ Incisional biopsy
- ☐ Excisional biopsy
- ☐ Resection, parotid gland
  - ☐ Superficial parotidectomy
  - ☐ Total parotidectomy
- ☐ Resection, submandibular gland
- ☐ Resection, sublingual gland
- ☐ Neck (lymph node) dissection (specify): \_\_\_\_\_
- ☐ Other (specify): \_\_\_\_\_
- ☐ Not specified

**\*Specimen Integrity**

- \* ☐ Intact
- \* ☐ Fragmented

**Specimen Size**

Greatest dimensions: \_\_\_\_ x \_\_\_\_ x \_\_\_\_ cm

\*Additional dimensions (if more than one part): \_\_\_\_ x \_\_\_\_ x \_\_\_\_ cm

**Specimen Laterality**

- ☐ Right
- ☐ Left
- ☐ Bilateral
- ☐ Not specified

\* Data elements with asterisks are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management.

**Tumor Site (select all that apply) (Note A)**

- ☐ Parotid gland
  - ☐ Superficial lobe
  - ☐ Deep lobe
  - ☐ Entire parotid gland
- ☐ Submandibular gland
- ☐ Sublingual gland
- ☐ Other (specify): \_\_\_\_\_
- ☐ Not specified

**Tumor Focality**

- ☐ Single focus
- ☐ Bilateral
- ☐ Multifocal (specify): \_\_\_\_\_

**Tumor Size**

- Greatest dimension: \_\_\_\_ cm
- \*Additional dimensions: \_\_\_\_ x \_\_\_\_ cm
- ☐ Cannot be determined (see Comment)

**\*Tumor Description (select all that apply)**

- \* ☐ Encapsulated/circumscribed
- \* ☐ Invasive
- \* ☐ Solid
- \* ☐ Cystic
- \* ☐ Other (specify): \_\_\_\_\_

**\*Macroscopic Extent of Tumor (extent of invasion)**

\*Specify: \_\_\_\_\_

**Histologic Type (select all that apply) (Note B)**

- ☐ Acinic cell carcinoma
- ☐ Adenoid cystic carcinoma
- ☐ Adenocarcinoma, not otherwise specified (NOS)
  - ☐ Low grade
  - ☐ Intermediate grade
  - ☐ High grade
- ☐ Basal cell adenocarcinoma
- ☐ Carcinoma ex pleomorphic adenoma (malignant mixed tumor)
  - ☐ Low-grade
  - ☐ High-grade
  - ☐ Invasive
    - ☐ Minimally invasive (**Note C**)
    - ☐ Invasive (**Note C**)
  - ☐ Intracapsular (noninvasive)
- ☐ Carcinosarcoma (true malignant mixed tumor)
- ☐ Clear cell adenocarcinoma
- ☐ Cystadenocarcinoma
- ☐ Epithelial-myoepithelial carcinoma
- ☐ Large cell carcinoma
- ☐ Low-grade cribriform cystadenocarcinoma

\* Data elements with asterisks are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management.

- ☐ Lymphoepithelial carcinoma
- ☐ Metastasizing pleomorphic adenoma
- ☐ Mucoepidermoid carcinoma
  - ☐ Low grade
  - ☐ Intermediate grade
  - ☐ High grade
- ☐ Mucinous adenocarcinoma (colloid carcinoma)
- ☐ Myoepithelial carcinoma (malignant myoepithelioma)
- ☐ Oncocytic carcinoma
- ☐ Polymorphous low-grade adenocarcinoma
- ☐ Salivary duct carcinoma
- ☐ Sebaceous adenocarcinomas
  - ☐ Sebaceous adenocarcinoma
  - ☐ Sebaceous lymphadenocarcinoma
- ☐ Sialoblastoma
- ☐ Small cell (neuroendocrine) carcinoma
- ☐ Squamous cell carcinoma, primary
- ☐ Undifferentiated carcinoma, large cell type
- ☐ Other (specify): \_\_\_\_\_
- ☐ Carcinoma, type cannot be determined

**Histologic Grade (Note C)**

- ☐ Not applicable
- ☐ GX: Cannot be assessed
- ☐ G1: Well differentiated
- ☐ G2: Moderately differentiated
- ☐ G3: Poorly differentiated
- ☐ Other (specify): \_\_\_\_\_

**\*Microscopic Tumor Extension**

\*Specify: \_\_\_\_\_

**Margins (Notes D and E)**

- ☐ Cannot be assessed
- ☐ Margins uninvolved by carcinoma
  - Distance of tumor from closest margin: \_\_\_\_ mm or \_\_\_\_ cm
  - Specify margin, if possible: \_\_\_\_\_
- ☐ Margin(s) involved by carcinoma
  - Specify margin(s), if possible: \_\_\_\_\_

**\*Treatment Effect (applicable to carcinomas treated with neoadjuvant therapy)**

- \* ☐ Not identified
- \* ☐ Present (specify): \_\_\_\_\_
- \* ☐ Indeterminate

\* Data elements with asterisks are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management.

**Lymph-Vascular Invasion**

- ☐ Not identified
- ☐ Present
- ☐ Indeterminate

**Perineural Invasion (Note F)**

- ☐ Not identified
- ☐ Present
- ☐ Indeterminate

**Lymph Nodes, Extranodal Extension (Note G)**

- ☐ Not identified
- ☐ Present
- ☐ Indeterminate

**Pathologic Staging (pTNM) (Note H)**

*Note: The phrases in italics include clinical findings required for AJCC staging. This clinical information may be unknown to the pathologist. It is included here only for the sake of completeness.*

**TNM Descriptors** (required only if applicable) (select all that apply)

- ☐ m (multiple primary tumors)
- ☐ r (recurrent)
- ☐ y (post-treatment)

**Primary Tumor (pT)**

- ☐ pTX: Cannot be assessed
- ☐ pT0: No evidence of primary tumor
- ☐ pT0: No evidence of primary tumor
- ☐ pT1: Tumor 2 cm or less in greatest dimension *without extraparenchymal extension (Note I)*
- ☐ pT2: Tumor more than 2 cm but not more than 4 cm in greatest dimension *without extraparenchymal extension (Note I)*
- ☐ pT3: Tumor more than 4 cm and/or tumor *having extraparenchymal extension (Note I)*
- ☐ pT4a: Moderately advanced disease. Tumor invades skin, mandible, ear canal, and/or facial nerve.
- ☐ pT4b: Very advanced local disease. Tumor invades skull base and/or pterygoid plates and/or encases carotid artery

*Note: There is no category of carcinoma in situ (pTis) relative to carcinomas of salivary glands (major, minor).*

\* Data elements with asterisks are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management.

Regional Lymph Nodes (pN)<sup>#</sup> (Notes J through M)

- ☐ pNX: Cannot be assessed  
☐ pN0: No regional lymph node metastasis  
☐ pN1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension  
☐ pN2a: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension  
☐ pN2b: Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension  
☐ pN2c: Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension  
☐ pN3: Metastasis in a lymph node, more than 6 cm in greatest dimension

Specify: Number examined: \_\_\_\_  
 Number involved: \_\_\_\_  
 \*Size (greatest dimension) of the largest positive lymph node: \_\_\_\_  
**(Note L)**

<sup>#</sup> Superior mediastinal lymph nodes are considered regional lymph nodes (level VII).  
 Midline nodes are considered ipsilateral nodes.

Distant Metastasis (pM)

- ☐ Not Applicable  
☐ pM1: Distant metastasis  
 \*Specify site(s), if known: \_\_\_\_\_

**\*Additional Pathologic Findings (select all that apply)**

- \* ☐ Sialadenitis  
 \* ☐ Tumor associated lymphoid proliferation (TALP)  
 \* ☐ Other (specify): \_\_\_\_\_

**\*Ancillary Studies (Note N)**

- \*Specify type(s): \_\_\_\_\_  
 \*Specify result(s): \_\_\_\_\_

**\*Clinical History (select all that apply)**

- \* ☐ Neoadjuvant therapy  
     \* ☐ Yes (specify type): \_\_\_\_\_  
     \* ☐ No  
     \* ☐ Indeterminate  
 \* ☐ Other (specify): \_\_\_\_\_

**\*Comment(s)**

\* Data elements with asterisks are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management.

## Explanatory Notes

---


### Scope of Guidelines

The reporting of oral cancer including the lip is facilitated by the provision of a checklist illustrating the features required for comprehensive patient care. However, there are many cases in which the individual practicalities of applying such a checklist may not be straightforward. Common examples include finding the prescribed number of lymph nodes, trying to determine the levels of the radical neck dissection, and determining if isolated tumor cells in a lymph node represent metastatic disease. Checklists have evolved to include clinical, radiographic, morphologic, immunohistochemical, and molecular results in an effort to guide clinical management. Adjuvant and neoadjuvant therapy can significantly alter histologic findings, making accurate classification an increasingly complex and demanding task. This checklist tries to remain simple while still incorporating important pathologic features as proposed by the American Joint Committee on Cancer (AJCC) cancer staging manual, the World Health Organization classification of tumours, the TNM classification, the American College of Surgeons Commission on Cancer, and the International Union on Cancer (UICC). This checklist is to be used as a guide and resource, an adjunct to diagnosing and managing cancers of the oral cavity in a standardized manner. It should not be used as a substitute for dissection or grossing techniques and does not give histologic parameters to reach the diagnosis. Subjectivity is always a factor, and elements listed are not meant to be arbitrary but are meant to provide uniformity of reporting across all the disciplines that use the information. It is a foundation of practical information that will help to meet the requirements of daily practice to benefit both clinicians and patients alike.

### A. Primary Site (Figure 1)

The classification applies only to carcinomas of the major salivary glands: parotid, submandibular (submaxillary), and sublingual glands.<sup>1</sup> Tumors arising in minor salivary glands (mucous-secreting glands in the lining membrane of the upper aerodigestive tract) are staged according to the classification schemes corresponding to the anatomic sites in which they reside, eg, oral cavity, pharynx, sinonasal tract.





**Figure 1.** Anatomy of the major salivary glands. From: *Gray's Anatomy*. 39th ed. Edinburgh: Elsevier Churchill Livingstone; 2005. Reproduced with permission © Elsevier.

## B. Histological Type

The histologic classification recommended is a modification of the World Health Organization (WHO) classification of salivary gland tumors.<sup>2,3</sup> The listing is in alphabetical order and includes the following:

- Acinic cell carcinoma
- Adenoid cystic carcinoma
- Adenocarcinoma (not otherwise specified [NOS])
  - Low grade
  - Intermediate grade
  - High grade
- Basal cell adenocarcinoma
- Carcinoma ex pleomorphic adenoma (malignant mixed tumor)
  - Low grade
  - High grade
  - Invasive (minimally invasive; invasive)
  - Intracapsular (noninvasive)
- Carcinoma, type cannot be determined
- Carcinosarcoma (true malignant mixed tumor)
- Clear cell adenocarcinoma
- Cystadenocarcinoma
- Epithelial-myoeipithelial carcinoma
- Large cell carcinoma
- Low-grade cribriform cystadenocarcinoma
- Lymphoepithelial carcinoma
- Metastasizing pleomorphic adenoma<sup>#</sup>

Mucoepidermoid carcinoma

Low grade

Intermediate grade

High grade

Mucinous adenocarcinoma (colloid carcinoma)

Myoepithelial carcinoma (malignant myoepithelioma)

Oncocytic carcinoma

Polymorphous low-grade adenocarcinoma

Salivary duct carcinoma

Sebaceous adenocarcinomas

Sebaceous adenocarcinoma

Sebaceous lymphadenocarcinoma

Sialoblastoma

Small cell (neuroendocrine) carcinoma

Squamous cell carcinoma, primary

Undifferentiated carcinoma, large cell type

# Metastatic foci are histologically benign. Although not strictly considered a malignant neoplasm, this neoplasm is classified with other salivary gland carcinomas<sup>2,3</sup> given the fact that 40% of patients are reported to die of disease even though 60% are alive and well (47%) or are alive with disease (13%).<sup>4</sup>

### C. Histologic Grade

The histologic (microscopic) grading of salivary gland carcinomas has been shown to be an independent predictor of behavior and plays a role in optimizing therapy.<sup>3,5-8</sup> Further, there is often a positive correlation between histologic grade and clinical stage. For the majority of salivary gland carcinomas there is only a single histologic grade and classification alone determines the histologic grade (eg, acinic cell carcinoma is a histologically low-grade carcinoma; salivary duct carcinoma is a histologically high-grade carcinoma). With some exceptions, histologic grading is predicated on cytomorphic features. In this histologic grading scheme, 3 histologic grades are suggested, as follows:

Grade 1	Well differentiated = Low-grade
Grade 2	Moderately differentiated = Intermediate-grade
Grade 3	Poorly differentiated = High-grade
Grade X	Cannot be assessed

When a tumor manifests more than 1 grade of differentiation, the surgical report must designate both the highest and the most prevalent tumor grades. In some carcinomas, histologic grading may be based on growth pattern, such as in adenoid cystic carcinoma, for which a histologic high-grade variant has been recognized based on the percentage of solid growth.<sup>3</sup> Those adenoid cystic carcinomas showing 30% or greater of solid growth pattern are considered to be histologically high-grade carcinomas.<sup>3,6,9</sup> The histologic grading of mucoepidermoid carcinoma includes a combination of growth pattern characteristics (eg, cystic, solid, neurotropism) and cytomorphic findings (eg, anaplasia, mitoses, necrosis).<sup>10-12</sup>

Carcinoma ex pleomorphic adenoma is subclassified by histologic grade (low-grade and high-grade) and extent of invasion, the latter including minimally invasive, invasive, and noninvasive cancers. Minimally invasive cancers measure less than or equal to 1.5 mm

with penetration of the malignant component into extracapsular tissue; invasive carcinomas measure more than 1.5 mm of invasion; noninvasive cancers are completely confined within the capsule without evidence of penetration into extracapsular tissue. Prior to diagnosing a noninvasive carcinoma ex pleomorphic adenoma, sectioning of the entire lesion for histologic evaluation is recommended in order to exclude the presence of invasive growth. Prognosis has been linked to degree of invasion with noninvasive and minimally invasive cancers apparently having a better prognosis than invasive cancers.<sup>13</sup>

#### **D. Surgical Margins**

Complete surgical excision to include cancer-free surgical margins is the primary mode of therapy for salivary gland cancers, as retrospective studies have shown an increased risk for recurrence and decreased survival with positive surgical margins.<sup>14-18</sup> The need for additional surgery is determined on the basis of histopathologic review; positive surgical margins are an indication for additional resection to ensure total tumor removal. There is no category of carcinoma in situ relative to carcinomas of salivary glands (major, minor) with the exception of the rare, purely in situ, low-grade cribriform cystadenocarcinoma (also referred to as intraductal carcinoma).<sup>3</sup>

#### **E. Orientation of Specimen**

Complex specimens should be examined and oriented with the assistance of attending surgeons. Direct communication between the surgeon and pathologist is a critical component in specimen orientation and proper sectioning. Whenever possible, the tissue examination request form should include a drawing of the resected specimen showing the extent of the tumor and its relation to the anatomic structures of the region. The lines and extent of the resection can be depicted on preprinted adhesive labels and attached to the surgical pathology request forms.

#### **F. Perineural Invasion**

The presence of perineural invasion (neurotropism) is an important predictor of poor prognosis in head and neck cancer of virtually all sites.<sup>19</sup> The majority of studies evaluating the influence of perineural invasion on therapy and prognosis are limited to head and neck squamous cell carcinoma. However, relative to salivary gland carcinomas, facial nerve dysfunction and perineural involvement are factors influencing the indication for neck dissection, postoperative radiation therapy, and survival rate. Perineural invasion (neurotropism) in the primary salivary gland carcinomas, especially the facial nerve, is associated with recurrent tumor and decreased survival.<sup>3</sup> Further, facial nerve involvement by carcinoma has been found to be predictive of occult metastases.<sup>20,21</sup> Among other prognostic indicators, perineural invasion in minor salivary gland tumors has been shown to be statistically significant to the outcome.<sup>22</sup> Given the significance relative to prognosis and treatment, perineural invasion is a required data element in the reporting of salivary gland carcinomas.

#### **G. Extranodal Extension**

The status of cervical lymph nodes is the single most important prognostic factor in aerodigestive cancer. All macroscopically negative or equivocal lymph nodes should be submitted *in toto*. Grossly positive nodes may be partially submitted for microscopic documentation of metastasis. Reporting of lymph nodes containing metastasis should include whether there is presence or absence of extra-nodal extension (EE). This finding consists of extension of metastatic tumor, present within the confines of the lymph node, through the lymph node capsule into the surrounding connective tissue, with or without

associated stromal reaction. If macroscopic examination suggests EE, this tissue should be submitted for microscopic confirmation. EE is a predictor of regional relapse and a criterion for postoperative radiotherapy.<sup>23-25</sup>

### H. TNM and Stage Groupings

The protocol recommends the TNM staging system of the American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC) for salivary gland cancer.<sup>1,26</sup>

#### Primary Tumor

- TX Primary tumor cannot be assessed
- T0 No evidence of primary tumor
- T1 Tumor 2 cm or less in greatest dimension without extraparenchymal extension
- T2 Tumor more than 2 cm but not more than 4 cm in greatest dimension without extraparenchymal extension
- T3 Tumor more than 4 cm and/or tumor having extraparenchymal extension
- T4a Moderately advanced disease. Tumor invades skin, mandible, ear canal, and/or facial nerve
- T4b Very advanced disease. Tumor invades skull base and/or pterygoid plates and/or encases carotid artery

#### Regional Lymph Nodes<sup>#</sup>

- NX Cannot be assessed
- N0 No regional lymph node metastasis
- N1 Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension
- N2a Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension
- N2b Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension
- N2c Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension
- N3 Metastasis in a lymph node, more than 6 cm in greatest dimension

<sup>#</sup>Superior mediastinal lymph nodes are considered regional lymph nodes (level VII). Midline nodes are considered ipsilateral nodes.

#### Distant Metastasis

- M0 No distant metastasis
- M1 Distant metastasis

By AJCC/UICC convention, the designation “T” refers to a primary tumor that has not been previously treated. The symbol “p” refers to the pathologic classification of the TNM, as opposed to the clinical classification, and is based on gross and microscopic examination. pT entails a resection of the primary tumor or biopsy adequate to evaluate the highest pT category, pN entails removal of nodes adequate to validate lymph node metastasis, and pM implies microscopic examination of distant lesions. Clinical classification (cTNM) is usually carried out by the referring physician before treatment during initial evaluation of the patient or when pathologic classification is not possible.

Pathologic staging is usually performed after surgical resection of the primary tumor. Pathologic staging depends on pathologic documentation of the anatomic extent of

disease, whether or not the primary tumor has been completely removed. If a biopsied tumor is not resected for any reason (eg, when technically unfeasible) and if the highest T and N categories or the M1 category of the tumor can be confirmed microscopically, the criteria for pathologic classification and staging have been satisfied without total removal of the primary cancer.

Significant changes in the AJCC staging manual<sup>1</sup> include revision of T3 to include all tumors larger than 4cm and division of T4 lesions into T4a and T4b. T4a tumors invade skin, mandible, ear canal, and/or facial nerve. T4b tumors invade skull base and/or pterygoid plates and/or encases carotid artery. T4a are advanced tumors that can be resected with clear margins; T4b are advanced tumors that cannot be resected with clear margins.

### Stage Groupings

Stage I	T1	N0	M0
Stage II	T2	N0	M0
Stage III	T3	N0	M0
	T1,T2,T3	N1	M0
Stage IVA	T4a	N0	M0
	T4a	N1	M0
	T1,T2,T3,T4a	N2	M0
Stage IVB	T4b	Any N	M0
	Any T	N3	M0
Stage IVC	Any T	Any N	M1

### TNM Descriptors

For identification of special cases of TNM or pTNM classifications, the “m” suffix and “y,” “r,” and “a” prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.

The “m” suffix indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.

The “y” prefix indicates those cases in which classification is performed during or following initial multimodality therapy (ie, neoadjuvant chemotherapy, radiation therapy, or both chemotherapy and radiation therapy). The cTNM or pTNM category is identified by a “y” prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The “y” categorization is not an estimate of tumor prior to multimodality therapy (ie, before initiation of neoadjuvant therapy).

The “r” prefix indicates a recurrent tumor when staged after a documented disease-free interval, and is identified by the “r” prefix: rTNM.

The “a” prefix designates the stage determined at autopsy: aTNM.

### Additional Descriptors

#### Residual Tumor (R)

Tumor remaining in a patient after therapy with curative intent (eg, surgical resection for cure) is categorized by a system known as R classification, shown below.

RX	Presence of residual tumor cannot be assessed
R0	No residual tumor
R1	Microscopic residual tumor
R2	Macroscopic residual tumor

For the surgeon, the R classification may be useful to indicate the known or assumed status of the completeness of a surgical excision. For the pathologist, the R classification is relevant to the status of the margins of a surgical resection specimen. That is, tumor involving the resection margin on pathologic examination may be assumed to correspond to residual tumor in the patient and may be classified as macroscopic or microscopic according to the findings at the specimen margin(s).

### I. Extraparenchymal Extension

Extraparenchymal extension is clinical or macroscopic evidence of invasion of soft tissues or nerve (T1, T2, T3), except those listed under T4a and 4b. Microscopic evidence alone does not constitute extraparenchymal extension for classification purposes.<sup>1</sup>

### J. Classification of Neck Dissection

1. Radical neck dissection
2. Modified radical neck dissection, internal jugular vein and/or sternocleidomastoid muscle spared
3. Selective neck dissection (SND), as specified by the surgeon
  - a. Supraomohyoid neck dissection
  - b. Posterolateral neck dissection
  - c. Lateral neck dissection
  - d. Central compartment neck dissection
4. Selective neck dissection (SND), as specified by the surgeon -“SND” with levels and sublevels designated (**Figure 2**)<sup>27-29</sup>
5. Extended radical neck dissection, as specified by the surgeon

### K. Regional Lymph Nodes (pN0): Isolated Tumor Cells

Isolated tumor cells (ITCs) are single cells or small clusters of cells not more than 0.2 mm in greatest dimension. Lymph nodes or distant sites with ITCs found by either histologic examination, immunohistochemistry, or non-morphologic techniques (eg, flow cytometry, DNA analysis, polymerase chain reaction [PCR] amplification of a specific tumor marker) should be classified as N0 or M0, respectively. Specific denotation of the assigned N category is suggested as follows for cases in which ITCs are the only evidence of possible metastatic disease.<sup>30,31</sup>

pN0	No regional lymph node metastasis histologically, no examination for isolated tumor cells (ITCs)
pN0(i-)	No regional lymph node metastasis histologically, negative morphologic (any morphologic technique, including hematoxylin-eosin and immunohistochemistry) findings for ITCs
pN0(i+)	No regional lymph node metastasis histologically, positive morphologic (any morphologic technique, including hematoxylin-eosin and immunohistochemistry) findings for ITCs
pN0(mol-)	No regional lymph node metastasis histologically, negative non-morphologic (molecular) findings for ITCs

pN0(mol+) No regional lymph node metastasis histologically, positive non-morphologic (molecular) findings for ITCs

For purposes of pathologic evaluation, lymph nodes are organized by levels as shown in Figure 2.<sup>32</sup>



**Figure 2.** The six sublevels of the neck for describing the location of lymph nodes within levels I, II, and V. Level IA, submental group; level IB, submandibular group; level IIA, upper jugular nodes along the carotid sheath, including the subdigastric group; level IIB, upper jugular nodes in the submuscular recess; level VA, spinal accessory nodes; and level VB, the supraclavicular and transverse cervical nodes. From: Flint PW, et al, eds. *Cummings Otolaryngology: Head and Neck Surgery*. 5th ed. Philadelphia, PA; Saunders: 2010. Reproduced with permission © Elsevier.

In order for pathologists to properly identify these nodes, they must be familiar with the terminology of the regional lymph node groups and with the relationships of those groups to the regional anatomy. Which lymph node groups surgeons submit for histopathologic evaluation depends on the type of neck dissection they perform. Therefore, surgeons must supply information on the types of neck dissections that they perform and the details of the local anatomy in the specimens they submit for examination or, in other manners, orient those specimens for pathologists.

If it is not possible to assess the levels of lymph nodes (for instance, when the anatomic landmarks in the excised specimens are not specified), then the lymph node levels may be estimated as follows: level II, upper third of internal jugular (IJ) vein or neck specimen; level III, middle third of IJ vein or neck specimen; level IV, lower third of IJ vein or neck specimen, all anterior to the sternocleidomastoid muscle.

#### **Level I. Submental Group (Sublevel IA)**

Lymph nodes within the triangular boundary of the anterior belly of the digastric muscles and the hyoid bone.

#### **Level I. Submandibular Group (Sublevel IB)**

Lymph nodes within the boundaries of the anterior and posterior bellies of the digastric muscle and the body of the mandible. The submandibular gland is included in the specimen when the lymph nodes within this triangle are removed.

**Level II. Upper Jugular Group (Sublevels IIA and IIB)**

Lymph nodes located around the upper third of the internal jugular vein and adjacent spinal accessory nerve extending from the level of the carotid bifurcation (surgical landmark) or hyoid bone (clinical landmark) to the skull base. The posterior boundary is the posterior border of the sternocleidomastoid muscle, and the anterior boundary is the lateral border of the sternohyoid muscle.

**Level III. Middle Jugular Group**

Lymph nodes located around the middle third of the internal jugular vein extending from the carotid bifurcation superiorly to the omohyoid muscle (surgical landmark), or cricothyroid notch (clinical landmark) inferiorly. The posterior boundary is the posterior border of the sternocleidomastoid muscle, and the anterior boundary is the lateral border of the sternohyoid muscle.

**Level IV. Lower Jugular Group**

Lymph nodes located around the lower third of the internal jugular vein extending from the omohyoid muscle superiorly to the clavicle inferiorly. The posterior boundary is the posterior border of the sternocleidomastoid muscle, and the anterior boundary is the lateral border of the sternohyoid muscle.

**Level V. Posterior Triangle Group (Sublevels VA and VB)**

This group comprises predominantly the lymph nodes located along the lower half of the spinal accessory nerve and the transverse cervical artery. The supraclavicular nodes are also included in this group. The posterior boundary of the posterior triangle is the anterior border of the trapezius muscle, the anterior boundary of the posterior triangle is the posterior border of the sternocleidomastoid muscle, and the inferior boundary of the posterior triangle is the clavicle.

**Level VI. Anterior (Central) Compartment**

Lymph nodes in this compartment include the pre- and paratracheal nodes, precricoid (Delphian) node, and the perithyroidal nodes, including the lymph nodes along the recurrent laryngeal nerve. The superior boundary is the hyoid bone, the inferior boundary is the suprasternal notch, the lateral boundaries are the common carotid arteries, and the posterior boundary by the prevertebral fascia.

**Level VII. Superior Mediastinal Lymph Nodes**

Metastases at level VII are considered regional lymph node metastases; all other mediastinal lymph node metastases are considered distant metastases.

Lymph node groups removed from areas not included in the above levels, eg, scalene, suboccipital, and retropharyngeal, should be identified and reported from all levels separately. Midline nodes are considered ipsilateral nodes.

**L. Lymph Nodes****Lymph Node Number**

Histological examination of a selective neck dissection specimen will ordinarily include 6 or more lymph nodes. Histological examination of a radical or modified radical neck dissection specimen will ordinarily include 10 or more lymph nodes in the untreated neck.



**Measurement of Tumor Metastasis**

The cross-sectional diameter of the largest metastasis in a lymph node containing metastatic tumor is measured in the gross specimen at the time of macroscopic examination or, if necessary, on the histologic slide at the time of microscopic examination. There is conflicting data in the literature on the significance of the size of the largest metastatic lymph node on the risk of regional recurrence and a predictor of poor overall survival.<sup>19</sup> While the diameter of the largest positive lymph node may potentially serve as a predictor of outcome, it may not represent an independent predictor of outcome when other pathologic factors are considered.<sup>19</sup>

**M. Special Procedures for Lymph Nodes**

At the current time, no additional special techniques should be used other than routine histology for the assessment of nodal metastases. Immunohistochemistry and PCR to detect isolated tumor cells are considered investigational techniques at this time.

**N. Ancillary Testing**

At the current time, no additional special techniques are required other than routine histology for the assessment of salivary gland tumors. Immunohistochemical staining for HER2/*neu* can be identified in association with salivary duct carcinoma; however, at the present time there are no specific recommendations to perform confirmatory fluorescence in-situ hybridization (FISH) analysis similar to mammary duct carcinoma; the utilization of FISH analysis in salivary duct carcinoma or any other salivary gland malignancy is considered an investigational technique at this time. Salivary duct carcinomas frequently express immunoreactivity for hormonal receptors, including androgen receptor and estrogen receptor-beta (usually negative for estrogen receptor-alpha, the more commonly used estrogen immunohistochemical stain).<sup>33</sup> Although there are no specific recommendations to perform confirmatory immunohistochemistry for hormonal receptors, the expression of androgen receptor and estrogen receptor-beta may potentially guide treatment with targeted multiagent chemotherapies.<sup>33</sup>

**References**

1. Patel S, Shah JP. Part II: Head and neck sites. In: Edge SB, Byrd DR, Carducci MA, Compton CA, eds. *AJCC Cancer Staging Manual*. 7th ed. New York, NY: Springer; 2009.
2. Barnes L, Eveson JW, Reichart P, Sidransky D, eds. *World Health Organization Classification of Tumours: Pathology and Genetics of Head and Neck Tumours*. Lyon, France: IARC Press; 2005.
3. Ellis GL, Auclair PL. Salivary gland tumors. In: Silverberg SG, ed. *Tumors of the Salivary Glands. AFIP Atlas of Tumor Pathology*. Series 4. Fascicle 9. Washington, DC: Armed Forces Institute of Pathology; 2008.
4. Gnepp DR. Metastasizing pleomorphic adenoma. In *World Health Organization Classification of Tumours: Pathology and Genetics of Head and Neck Tumours*. Lyon, France: IARC Press; 2005.
5. Spiro RH, Huvos AG, Strong EW. Adenocarcinoma of salivary gland origin. Clinicopathologic study of 204 patients. *Am J Surg*. 1982;144:423-431.
6. Szanto PA, Luna MA, Tortoledo ME, White RA. Histologic grading of adenoid cystic carcinoma of the salivary glands. *Cancer*. 1984;84:1062-1069.
7. Spiro RH, Thaler HT, Hicks WF, Kher UA, Huvos AG, Strong EW. The importance of clinical staging in minor salivary gland carcinoma. *Am J Surg*. 1991;162:330-336.

8. Kane WJ, McCaffrey TV, Olsen KD, Lewis JE. Primary parotid malignancies: a clinical and pathologic review. *Arch Otolaryngol Head Neck Surg.* 1991;117:307-315.
9. Greiner TC, Robinson RA, Maves MD. Adenoid cystic carcinoma: a clinicopathologic study with flow cytometric analysis. *Am J Clin Pathol.* 1989;92:711-720.
10. Auclair PL, Goode RK, Ellis GL. Mucoepidermoid carcinoma of intraoral salivary glands: evaluation and application of grading criteria in 143 cases. *Cancer.* 1992;69:2021-30.
11. Goode RK, Auclair PL, Ellis GL. Mucoepidermoid carcinoma of the major salivary glands: clinical and histopathologic analysis of 234 cases with evaluation of grading criteria. *Cancer.* 1998;82:1217-24.
12. Brandwein MS, Ivanov K, Wallace DI, et al. Mucoepidermoid carcinoma: a clinicopathologic study of 80 patients with special reference to histological grading. *Am J Surg Pathol.* 2001;25:835-45.
13. Brandwein M, Huvos AG, Dardick I, et al. Noninvasive and minimally invasive carcinoma ex mixed tumor: a clinicopathologic and ploidy study of 12 patients with major salivary tumors of low (or no?) malignant potential. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 1996;81:655-664.
14. Tran L, Sadeghi A, Hanson D, et al. Major salivary gland tumors: treatment results and prognostic factors. *Laryngoscope.* 1986;96:1139-1144.
15. Vander Poorten VL, Balm AJM, Hilgers FJM, et al. The development of a prognostic score for patients with parotid carcinoma. *Cancer.* 1999;85:2057-2067.
16. O'Brien CJ, Soong SJ, Herrerra GA, et al. Malignant salivary gland tumors: analysis of prognostic factors and survival. *Head Neck.* 1986;9:82-92.
17. Malata CM, Camilleri IG, McLean MR, et al. Malignant tumors of the parotid gland: a 12-year review. *Br J Plast Surg.* 1997;50:600-608.
18. Tullio A, Marchetti C, Sessena E, et al. Treatment of carcinoma of the parotid gland: the results of a multicenter study. *J Oral Maxillofac Surg.* 2001;59:263-270.
19. Smith BD, Haffty BG. Prognostic factors in patients with head and neck cancer. In: Harrison LB, Sessions RB, Hong WK, eds. *Head and Neck Cancer: A Multidisciplinary Approach.* 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2009: 51-75.
20. Frankenthaler RA, Byers RM, Luna MA, et al. Predicting lymph node metastasis in parotid cancer. *Arch Otolaryngol Head Neck Surg.* 1993;119:517-520.
21. Regis de Brito Santos I, Kowalski LP, Cavalcante de Araujo V, Falvia Logullo A, Magrin J. Multivariate analysis of risk factors for neck metastases in surgically treated parotid cancers. *Arch Otolaryngol Head Neck Surg.* 2001;127:56-60.
22. Copelli C, Bianchi B, Ferrari S, Ferri A, Sessena E. Malignant tumors of intraoral minor salivary glands. *Oral Oncol.* 2008;44:658-663.
23. Woolgar J, Triantafyllou A. Neck dissections: a practical guide for the reporting histopathologist. *Curr Diag Pathol.* 2007;13:499-511.
24. Leemans CR, Tiwari R, Nauta JJ, van der Waal I, Snow GB. Regional lymph node involvement and its significance in the development of distant metastases in head and neck carcinoma. *Cancer.* 1993;71:452-456.
25. Johnson JT, Barnes EL, Meyers EN, et al. The extracapsular spread of tumors in cervical node metastases. *Head Neck Surg.* 1981;107:725-729.
26. Sobin LH, Gospodarowicz MK, Wittekind CH, eds. *UICC TNM Classification of Malignant Tumors.* 7<sup>th</sup> ed. New York, NY: Wiley-Liss; in press.
27. Robbins KT, et al. Neck dissection classification update. *Arch Otolaryngol Head Neck Surg.* 2002;128:751-758.

28. Robbins TK. et al. Consensus statement on the classification and terminology of neck dissection. *Arch Otolaryngol Head Neck Surg.* 2008;134:536-538.
29. Robbins T, Medina JE, Wolfe GT, Levine PA, Sessions RB, Pruet CW. Standardizing neck dissection terminology: official report of the academy's committee for head and neck surgery and oncology. *Arch Otolaryngol Head Neck Surg.* 1991;117:601-605.
30. Wittekind C, Greene FL, Henson DE, Hutter RVP, Sobin LH, eds. *TNM Supplement: A Commentary on Uniform Use.* 3<sup>rd</sup> ed. New York: Wiley-Liss; 2003.
31. Singletary SE, Greene FL, Sobin LH. Classification of isolated tumor cells: clarification of the 6<sup>th</sup> edition of the American Joint Committee on Cancer Staging Manual. *Cancer.* 2003;90(12):2740-2741.
32. Flint PW, et al, eds. *Cummings Otolaryngology: Head and Neck Surgery.* 4th ed. Philadelphia, PA: Saunders; 2010.
33. Williams MD, Roberts D, Blumenschein GR, et al. Differential expression of hormonal and growth factor receptors in salivary duct carcinomas. Biologic significance and potential role in therapeutic stratification of patients. *Am J Surg Pathol* 2007;31:1645-1652.